PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25766467-0 2015 Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. Losartan 25-33 angiotensin I converting enzyme 2 Rattus norvegicus 49-53 26857347-10 2016 Losartan decreased cardiac hypertrophy and fibrosis and improved left ventricle fraction of shortening in P28 O2-exposed rats, which was associated with decreased oxidation of calcium/calmodulin-dependent protein kinase II, inhibition of the transforming growth factor-beta/SMAD3 pathway, and upregulation of cardiac angiotensin-converting enzyme 2. Losartan 0-8 angiotensin I converting enzyme 2 Rattus norvegicus 317-348 25795458-5 2015 Compared with cigarette exposure group, after losartan treatment, RVSP, ACE and AngII obviously decreased (P<0.05), and ACE2 expression levels significantly increased. Losartan 46-54 angiotensin I converting enzyme 2 Rattus norvegicus 123-127 25575522-6 2014 Losartan treatment significantly decreased MAP, left ventricle hypertrophy (LVH), fibrosis, and increased cardiac ACE2 and Mas expression. Losartan 0-8 angiotensin I converting enzyme 2 Rattus norvegicus 114-118 20178811-3 2010 Losartan, a specific angiotensin II receptor antagonist, is a well-known antihypertensive drug with a potential role in regulating angiotensin-converting enzyme-2 (ACE2), a recently found regulator of RAS. Losartan 0-8 angiotensin I converting enzyme 2 Rattus norvegicus 131-162 20178811-3 2010 Losartan, a specific angiotensin II receptor antagonist, is a well-known antihypertensive drug with a potential role in regulating angiotensin-converting enzyme-2 (ACE2), a recently found regulator of RAS. Losartan 0-8 angiotensin I converting enzyme 2 Rattus norvegicus 164-168 20178811-6 2010 Losartan administration ameliorated pulmonary vascular remodeling, inhibited the smoke-induced RVSP and Ang II elevation and partially reversed the ACE2 decrease in rat lungs. Losartan 0-8 angiotensin I converting enzyme 2 Rattus norvegicus 148-152 20178811-9 2010 Consistent with the in vivo study, in vitro losartan pretreatment also inhibited cigarette smoke extract (CSE)-induced cell proliferation and ACE2 reduction in rat PASMCs. Losartan 44-52 angiotensin I converting enzyme 2 Rattus norvegicus 142-146 15007027-8 2004 Both losartan and olmesartan completely reversed the reduction in cardiac AT1a-R mRNA observed after coronary artery ligation while augmenting ACE 2 mRNA by approximately 3-fold. Losartan 5-13 angiotensin I converting enzyme 2 Rattus norvegicus 143-148 18849338-4 2008 ANG II significantly reduced ACE2 activity and downregulated ACE2 mRNA in cardiac myocytes, effects blocked by the ARB losartan, indicating that ANG II regulates ACE2. Losartan 119-127 angiotensin I converting enzyme 2 Rattus norvegicus 29-33 18849338-4 2008 ANG II significantly reduced ACE2 activity and downregulated ACE2 mRNA in cardiac myocytes, effects blocked by the ARB losartan, indicating that ANG II regulates ACE2. Losartan 119-127 angiotensin I converting enzyme 2 Rattus norvegicus 61-65 18849338-4 2008 ANG II significantly reduced ACE2 activity and downregulated ACE2 mRNA in cardiac myocytes, effects blocked by the ARB losartan, indicating that ANG II regulates ACE2. Losartan 119-127 angiotensin I converting enzyme 2 Rattus norvegicus 61-65 16766648-4 2006 Lisinopril induced a 3.1-fold (P < 0.05) increase in renal cortical expression of ACE2, whereas losartan increased ACE2 mRNA 3.5-fold (P < 0.05). Losartan 96-104 angiotensin I converting enzyme 2 Rattus norvegicus 115-119 16176966-4 2006 The ANG II-mediated reduction in ACE2 mRNA was blocked by the angiotensin type 1 (AT(1)) receptor antagonists losartan or valsartan; the angiotensin type 2 (AT(2)) antagonist PD123319 was ineffective. Losartan 110-118 angiotensin I converting enzyme 2 Rattus norvegicus 33-37 16176966-5 2006 The reduction in ACE2 mRNA by ANG II also was associated with a 50% decrease in cerebellar and medullary ACE2 protein, which was blocked by losartan. Losartan 140-148 angiotensin I converting enzyme 2 Rattus norvegicus 17-21 16176966-5 2006 The reduction in ACE2 mRNA by ANG II also was associated with a 50% decrease in cerebellar and medullary ACE2 protein, which was blocked by losartan. Losartan 140-148 angiotensin I converting enzyme 2 Rattus norvegicus 105-109 16221218-1 2005 BACKGROUND: Angiotensin-converting enzyme (ACE)2, a homologue of ACE, which is insensitive to ACE inhibitors and forms angiotensin-(1-7) [Ang-(1-7)] from angiotensin II (Ang II) with high efficiency was investigated in response to chronic blockade with lisinopril, losartan, and both drugs combined. Losartan 265-273 angiotensin I converting enzyme 2 Rattus norvegicus 43-48 16221218-13 2005 Renal cortex ACE2 activity was significantly augmented in rats medicated with lisinopril or losartan but not changed in those given the combination. Losartan 92-100 angiotensin I converting enzyme 2 Rattus norvegicus 13-17 28442323-12 2017 Losartan enhanced OVX-induced up-regulation of ACE-1, AngII, angiotensin type 1 (AT1) receptor and RANKL expression, and increased ACE-2, Ang1-7, Mas and OPG expression in OVX animals. Losartan 0-8 angiotensin I converting enzyme 2 Rattus norvegicus 131-136 33711846-9 2021 While ACE2 level increased in the groups receiving a combination of tacrolimus and losartan or captopril, the level of increase was insignificant, compared to the group treated with tacrolimus alone. Losartan 83-91 angiotensin I converting enzyme 2 Rattus norvegicus 6-10